Fig. 1: The binding affinities and inhibition activities of 6L3-3P and 6L3-3P11K peptides to different variants of SARS-CoV-2. | Nature Communications

Fig. 1: The binding affinities and inhibition activities of 6L3-3P and 6L3-3P11K peptides to different variants of SARS-CoV-2.

From: Intranasal administration of broad-spectrum macrocyclic peptide inhibitor protects against SARS-CoV-2 Omicron variants

Fig. 1: The binding affinities and inhibition activities of 6L3-3P and 6L3-3P11K peptides to different variants of SARS-CoV-2.

a The binding affinities of 6L3-3P and 6L3-3P11K peptides to RBDs from different SARS-CoV-2 variants are evaluated using a BIAcore 8K system in single-cycle mode. Affinity values summarized are the means of two independent experiments. b Inhibition of 6L3-3P and 6L3-3P11K peptides against different SARS-CoV-2 variant pseudotyped viruses in Vero cells. The two groups are distinguished by color, and the color depth correlates with the inhibitory activity. The experiments were performed at least twice with two replicates (n = 2). See also Supplementary Fig. 3.

Back to article page